Adaptive Biotechnologies
Seattle
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $531.9M
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2022)
- Ticker: nasdaq:ADPT
- Website: adaptivebiotech.com
- Phone: (206) 659-0067
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/adaptive-biotechnologies-43769 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.